HLB said the company would present the two interim results of combination treatment of its rivoceranib with immune-oncology and cytotoxic antineoplastic drugs at the online World Conference on Lung Cancer (WCLC) 2021 on Sept. 13.
Please refer to the following website for further details: https://www.koreabiomed.com/news/articleView.html?idxno=12058